Iadademstat is a Small Molecule owned by Oryzon Genomics, and is involved in 8 clinical trials, of which 4 were completed, and 4 are planned.
Iadademstat (ORY-1001) is LSD1/KDM1A inhibitor. Lysine specific demethylase-1 (LSD1/KDM1A) is an epigenetic modulator that regulates gene expression by demethylating specifically some lysines in the histones. LSD1 forms part of protein complexes involved in transcriptional regulation, and misregulation of these transcriptional complexes may result in leukemia disease. ORY-1001 reduces leukemic stem cell potential, potently inhibits colony formation, overcomes the differentiation block in AML cells, and induces apoptosis/inhibits proliferation in AML cells.
The revenue for Iadademstat is expected to reach a total of $5.7bn through 2038. This change impacts the valuation of this asset and is an important factor to understand the current value of the drug in a clinical process. View the complete picture with the Iadademstat NPV Report.
Iadademstat is originated and owned by Oryzon Genomics.
Iadademstat (ORY-1001) is under development for the treatment of small cell lung cancer, newly diagnosed, relapsed and refractory acute myeloid leukemia (AML) and neuroendocrine carcinoma. The drug candidate is administered orally. It is a new molecular entity (NME). The drug candidate targets lysine specific demethylase-1 (LSD1, aka KDM1). It is developed based on epigenetic platform. It was also under development for solid tumors like prostate cancer and breast cancer.
Oryzon Genomics Overview
Oryzon Genomics (Oryzon) is a clinical-stage biopharmaceutical company that offers discovers and develops epigenetic therapies to treat oncology and neurodegenerative diseases. The company provides epigenetics, a regulatory system that controls gene expression without affecting the makeup of the genes themselves and provides regulation of gene transcription that has emerged as a key biological determinant of protein production and cellular differentiation. Its clinical-stage product include ORY-1001, an oncology product for treating acute leukemia disease; ORY-2001 for treating Alzheimer disease, Parkinson disease and others; and ORY-3001 for treating other indications of cancer. Oryzon provides therapeutic programs and collaborative research services. The company serves patients with cancers or neurodegenerative disorders. It operates office in Spain and the US. Oryzon is headquartered in Cornella de Llobregat, Barcelona, Spain.
The operating loss of the company was EUR19.7 million in FY2021, compared to an operating loss of EUR4.3 million in FY2020. The net loss of the company was EUR5.2 million in FY2021, compared to a net loss of EUR3.4 million in FY2020.
Quick View – Iadademstat
|Highest Development Stage|